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http://dx.doi.org/10.1016/j.jmii.2013Simultaneous central nervous system (CNS) infection with Cryptococcus and tuberculosis (TB)
is very rare. Despite improved therapeutic options, treatment of CNS cryptococcosis is still
difficult and needs invasive treatment modalities, such as intrathecal or intraventricular am-
photericin B, in refractory cases. We describe a patient with systemic lupus erythematosus
diagnosed with simultaneous cryptococcal and TB meningitis who had a poor response to intra-
venous liposomal amphotericin B and fluconazole, but was successfully treated with intraven-
tricular amphotericin B, in addition to anti-TB therapy.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The etiology of central nervous system (CNS) infections in
immunosuppressed patients varies widely. Opportunistic in-
fections due to Listeria monocytogenes, Mycobacteriumt of Infectious Diseases and
ity, Cerrahpasa Medical Fac-
l, Turkey.
om (B. Mete).
an Society of Microbiology. Publ
.04.009tuberculosis, or fungi such as Cryptococcus spp. should be
considered in the differential diagnosis of meningitis in pa-
tients with systemic lupus erythematosus (SLE) receiving
immunosuppressive agents.1 Simultaneous CNS cryptococcosis
and tuberculosis (TB) is a rare condition in immunosuppressed
patients and even more rare in immunocompetent individuals.
Treatment of cryptococcosis has improved with the
advent of polyene antifungal drugs. However, treatment
may be difficult and invasive modalities may be needed in
refractory cases of CNS cryptococcosis.2 Here we present a
rare case of CNS cryptococcal and TB infection.ished by Elsevier Taiwan LLC. All rights reserved.
Figure 1. Magnetic resonance image demonstrating bilateral
ventricular ependymal contrast enhancement indicative of
ventriculitis (arrows).
Figure 2. MRI demonstrating complete regression of ven-
triculitis after intraventricular amphotericin B.
290 B. Mete et al.Case report
A 45-year-old woman with SLE was admitted to our clinic
with headache, fever, nausea, vomiting, incontinence,
somnolence, and convulsions. She had been diagnosed with
SLE 10 years before on presentation with a malar rash and
polyarthritis. She had lupus involvement of the kidney, but
no CNS involvement. She was taking steroids (10 years,
approximately 16 mg methylprednisolone/day), hydroxy-
chloroquine and methotrexate (for 1 year; stopped 1 year
before admission), and non-steroidal anti-inflammatory
drugs (as needed). She had been on methylprednisolone
treatment (16 mg/day) for the last 2 years. Her SLE disease
activity index (SLEDAI) score was 10 on admission. Head-
ache, nausea, and vomiting were present for the previous 4
months. During the previous 2 months, fever, incontinence,
somnolence, and convulsions were added to the clinical
spectrum. The patient was conscious with limited cooper-
ation; she had neck stiffness and dysarthric speech. The
bilateral muscular strength of her lower extremities was 3/
5 and her deep tendon reflexes were hypoactive. Cranial
magnetic resonance imaging (MRI) demonstrated lesions in
the basal ganglia and hydrocephalus. Laboratory results for
whole blood were as follows: leukocytes, 6200 /mm3; he-
moglobin, 12 g/dL; platelets, 324,000 /mm3; C-reactive
protein (CRP), 170 mg/L (normal range 0e5); erythrocyte
sedimentation rate, 100 mm/hour; and anti-HIV, negative.
CSF results were as follows: leukocytes, 160 /mm3 (80%
lymphocytes); protein, 174 mg/L; and glucose, 20 mg/dL
(simultaneous blood glucose, 144 mg/dL). Empirical anti-TB
therapy (rifampin þ isoniazid þ pyrazinamide þ ethambutol)
was initiated for a probable diagnosis of TB meningitis. One
week later, acid-fast bacilli were detected in a CSF sample
inoculated into mycobacterium growth indicator and were
identified as M. tuberculosis complex using polymerase
chain reaction (PCR). The isolate was found to be sensitive
to all of the major anti-TB drugs tested.
Although appropriate therapy was administered, the
clinical state of the patient deteriorated. She lost con-
sciousness during Week 2 of anti-TB therapy. Her Glasgow
coma scale score was 10/15 and left hemiparesis developed.
A repeat CSF examination on Day 15 of therapy revealed
capsulated yeasts using Indian ink staining, and Crypto-
coccus neoformans was isolated. Although liposomal
amphotericin B (5 mg/kg/day) was added to treat her
cryptococcal meningitis, the patient became unresponsive
to external stimuli by Week 3 of antifungal therapy. After
progression of hydrocephalus was detected by cranial MRI,
an external ventricular drain was applied to control CSF
pressure and fluconazole was added to liposomal ampho-
tericin B as flucytosine is not available in our country.
Repeated CSF cultures became sterile on this combination
therapy. The patient showed some improvement and
recovered minimal consciousness after 1 month of combi-
nation antifungal therapy, and CSF cultures were negative;
however, her fever persisted and MRI revealed ventriculitis
(Fig. 1). Although it did not fulfill the definition of persistent
infection, we decided to add intraventricular liposomal
amphotericin B based on the insufficient clinical response to
treatment. Following three doses of intraventricular lipo-
somal amphotericin B (1 mg/day every 72 hours), her feversubsided, CRP levels decreased, and radiological improve-
ment (Fig. 2) was observed. Repeated HIV tests remained
negative. Systemic liposomal amphotericin B was stopped in
Week 14 and oral fluconazole was discontinued after 6
months of treatment. Anti-TB treatment was continued for 1
year. The patient was referred to a physical therapy unit for
rehabilitation. Two years after completion of the therapy,
she was mobile with support and had only residual speech
impairment.
Table 1 Summary of seven reported cases and the present case of simultaneous cryptococcal and tuberculous meningiti
Ref. Age (y) Sex Clinical features Underlying
diseases
History of
pulmonary
TB
Microbiology Treatment Outcome
13 10 Male Fever, headache,
nausea, vomiting,
neck stiffness
comatose state
None CSF culture:
M. tuberculosis þ,
C. neoformans þ
SM þ INH þ promizole
for TB; ethyl vanillate
for C. neoformans
Discharged with
some spasticity
in left hand
and wrist
9 46 Female Fever, headache,
irritability,
progressive
drowsiness,
neck stiffness
(meningitis
1 y after
pulmonary
TB treatment)
Reticulum cell
sarcoma
(radiotherapy)
þ (Twice) CSF culture:
M. tuberculosis þ,
C. neoformans þ
INH and prednisone
for TB; sulfadiazine
for C. neoformans
(CSF TB culture
was negative
but cryptococci
were detected)
Exitus
(attributed
to renal
insufficiency
and E. coli
bacteremia)
8 31 Male Fever, meningismus,
convulsion,
comatose state
HIV infection Simultaneous CSF culture:
M. tuberculosis e
(TB diagnosis based
on radiological and
clinical findings); CSF
cryptococcal antigen þ
RIF þ INH þ
PZA þ EMB;
amphotericin B
Recovery
12 51 Male Fever, neck
stiffness,
right epididymitis
Chronic epididymitis
(biopsy culture
M. tuberculosis)
CSF culture:
M. tuberculosis þ,
C. neoformans
þ; CSF cryptococcal
antigen þ
RIF þ INH þ
PZA þ EMB;
amphotericin
B þ flucytosine
Recovery
10 61 Male Fever, mild
neck stiffness
Waldenstrom’s
macroglobulinemia
(treated with
fludarabine)
CSF and blood cultures
C. neoformans
þ; CSF and serum
cryptococcal antigen
þ; cerebral tissue cultu e:
M. tuberculosis þ
RIF þ INH þ
PZA þ EMB
for intracranial
tuberculoma;
amphotericin
B (4 wks)
Exitus (due to
septicemia)
11 25 Female Fever, cough,
headache,
vomiting,
neck and
lumbar stiffness
None CSF culture: M.
tuberculosis þ;
C. neoformans
þ; CSF cryptococcal
antigen þ
RIF þ INH þ
PZA þ EMB þ SM;
intravenous
fluconazole,
followed by
amphotericin B
Almost
complete
recovery
(continued on next page)
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Table 1 (continued )
Ref. Age (y) Sex Clinical features Underlying
diseases
History of
pulmonary
TB
Microbiology Treatment Outcome
14 43 Male Fever, confusion,
incontinence
HIV CSF culture:
C. neoformans þ;
CSF cryptococcal
antigen þ;
CSF PCR for
M. tuberculosis þ
RIF þ INH þ
PZA þ EMB;
amphotericin B
Recovery
Current
report
45 Female Fever, headache,
nausea, vomiting,
neck stiffness
incontinence,
somnolence,
convulsions
SLE with
steroid
therapy
CSF culture:
M. tuberculosis þ;
C. neoformans þ
RIF þ INH þ
PZA þ EMB;
intravenous
liposomal
amphotericin
B and fluconazole,
intraventricular
liposomal
amphotericin B
Discharged
(mobile with
support and
residual speech
impairment)
CSF Z cerebrospinal fluid; EMB Z ethambutol; HIV Z human immunodeficiency virus; INH Z isoniazid; PCR Z polymerase chain reaction; PZA Z pyrazinamide; RIF Z rifampin;
SLE Z systemic lupus erythematosus; SM Z streptomycin; TB Z tuberculosis.
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CNS TB is frequently encountered in regions where the
incidence of TB is high. HIV infection, intravenous drug use,
immunosuppression, immigration, and homelessness are
risk factors for TB development. Anti-TB therapy should be
initiated if clinical suspicion of CNS TB is high, as delayed
treatment contributes to morbidity and mortality.3
In Turkey, TB is the most common etiological agent leading
to chronic meningitis.4 According to a 2009 WHO report, the
TB prevalence rate is 25 per 100,000 in Turkey.5 The resis-
tance rate for isoniazid, rifampicin, isoniazid þ rifampicin,
ethambutol, and streptomycin is 13.1%, 6.5%, 5.1%, 4.7%, and
8.6%, respectively.6 As TB is moderately endemic in our
country and our patient had a history of extended cortico-
steroid use, empirical anti-TB therapy was started for a
probable diagnosis of TB meningitis.
Besides M. tuberculosis, fungi are also among the mi-
croorganisms that can cause chronic meningitis. The inci-
dence of infections caused by C. neoformans has markedly
increased over the past 20 years because of the increase in
the number of patients with HIV infection. Cryptococcal
meningitis may also occur in patients with other types of
immunosuppression and in immunocompetent patients.7
Simultaneous tuberculous and cryptococcal meningitis is
very rare. Seven cases of meningitis due to simultaneous C.
neoformans and M. tuberculosis infection have been re-
ported in the English literature.8e14 HIV infection, reticu-
lum cell sarcoma, and Waldenstrom’s macroglobulinemia
treated with fludarabine were underlying conditions in four
of these cases.8e10,14 One patient was an immigrant from
China.11 The characteristics for these seven cases are
summarized in Table 1. Our patient had received methyl-
prednisolone treatment for SLE for the previous 2 years.
Both corticosteroid therapy-related immunosuppression
and SLE disease itself were thought to be underlying factors
in the development of simultaneous CNS cryptococcosis and
TB in our case. Although the coexistence of both infections
has been reported to be rare in immunosuppressed hosts,
this situation might lead to underdiagnosis. Since co-
infection is so rare, the physician may diagnose either
disease: if an immunosuppressive patient is admitted with
clinical findings of CNS infection, any clue of TB or cryp-
tococcal infection might be accepted as a satisfactory
diagnostic finding. The accompanying second agent might
be missed because of lack of a thorough search.
CSF cell counts and protein and glucose levels may be
within the normal range in certain cases of TB or cryptococcal
meningitis, particularly in immunosuppressed patients.3,15
For immunosuppressed patients, the approach to CNS infec-
tion should include Indian ink and ErlicheZiehleNeelsen
(EZN) staining and mycobacterial culture of CSF to exclude TB
and cryptococcal meningitis. Baseline staining studies, such
as with Indian ink and EZN, may be helpful in guiding
empirical therapy.
Treatment of CNS cryptococcal infections used to be
challenging.16 Polyene antifungal drugs led to a dramatic
improvement in the outcome for individuals with crypto-
coccal meningitis. The Infectious Diseases Society of
America (IDSA) recently published a clinical practice
guideline for the management of cryptococcal disease.17According to this guideline, for patients who are not
infected with HIV and who have no history of trans-
plantation, combination therapy of amphotericin B plus
flucytosine for at least 4 weeks is followed by consolidation
therapy with fluconazole for 8 weeks. After induction and
consolidation therapy, maintenance therapy with flucona-
zole for 6e12 months is recommended.17
Combination therapy with amphotericin B and flucona-
zole for cryptococcal meningitis has mostly been limited to
animal studies, with a few human cases reported; however,
the new guideline recommends this as an alternative
treatment modality for patients infected with HIV.17
Barchiesi et al investigated the interaction between tri-
azoles and amphotericin B against C. neoformans. Although
they found antagonism between fluconazole and ampho-
tericin B in vitro, this antagonism was not observed in vivo.
They also suggested that the combination of triazoles and
amphotericin B was significantly more active than either
drug alone against C. neoformans in vitro.18
In our case, the patient became unresponsive to
external stimuli by Week 3 of parenteral liposomal
amphotericin B therapy. After progression of hydrocephalus
was detected by cranial MRI, an external drain was applied
and as flucytosine is not available in our country, flucona-
zole was added to liposomal amphotericin B.
Intraventricular administration of liposomal amphoter-
icin B for cryptococcal meningitis is preferred for cases who
are seriously ill or unresponsive to intravenous therapy.17
With concerns regarding complications associated with
multiple injections into the cisternal space via subcutane-
ous reservoirs,19 its use is not routinely recommended by
the IDSA.17 Systemic antifungal treatment failed in our case
but intraventricular administration of amphotericin B led to
a clinical improvement within 1 week and no adverse
events were observed during therapy.
In a study of 13 patients with cryptococcal meningitis,
CSF was sterile in all six patients receiving intraventricular
and systemic therapy, and in three of seven patients
receiving only systemic therapy.20 In our case, although the
patient showed some improvement and recovered minimal
consciousness after 1 month of systemic combination anti-
fungal therapy, fever persisted and MRI revealed ven-
triculitis. However, following intraventricular liposomal
amphotericin B therapy, a dramatic clinical and radiological
response was obtained.
In conclusion, the simultaneous presence of TB and
cryptococcal meningitis is a rare condition, but is deemed
possible in immunosuppressed patients. A combination of
amphotericin B and fluconazole and/or intraventricular
amphotericin B may be considered as alternative therapy in
patients with cryptoccocal meningitis refractory to stan-
dard therapy.
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